Polymorphisms in the TNFA and IL6 genes represent risk factors for autoimmune thyroid disease

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Durães, Cecília ^a   Moreira, Carla S ^a,b   Alvelos, Inês ^a   Mendes, Adélia ^a   Santos, Liliana R ^b,c   Machado, José Carlos ^a,b   Melo, Miguel ^a,c,d   Esteves, César ^e   Neves, Celestino ^b,e   Sobrinho Simões, Manuel ^a,b   Soares, Paula ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELE; ARTICLE; AUTOIMMUNE THYROID DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IL6 GENE; MAJOR CLINICAL STUDY; MALE; PORTUGAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID DISEASE; TNFA GENE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK FACTOR;

IL6 PROTEIN, HUMAN; INTERLEUKIN 6; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924382073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105492     Document Type: Article

References (60)

1. Sinha AA, Lopez MT, McDevitt HO (1990) Autoimmune diseases: the failure of self tolerance. Science 248: 1380-1388.
2. Caturegli P, Kimura H, Rocchi R, Rose NR (2007) Autoimmune thyroid diseases. Current Opinion in Rheumatology 19: 44-48. (Pubitemid 44885726)
3. Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS (2011) Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res 31: 721-731.
4. Weetman AP (2000) Chronic autoimmune thyroiditis. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. Braverman LE, Utiger RD ed. Philadelphia: Lippincott Williams and Wilkins. pp. 721-732.
5. Menconi F OY, Tomer Y (2008) Graves' disease. Diagnostic Criteria in Autoimmune Diseases. Y. Shoenfeld, R. Cervera, M.E. Gershwin ed. Totowa, NJ: Humana Press. pp. 231-235.
6. Tomer Y (2010) Genetic susceptibility to autoimmune thyroid disease: past, present, and future. Thyroid 20: 715-725.
7. Huber A, Menconi F, Corathers S, Jacobson EM, Tomer Y (2008) Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev 29: 697-725.
8. Bednarczuk T, Kurylowicz A, Hiromatsu Y, Kiljanskic J, Telichowska A, et al. (2004) Association of G-174C polymorphism of the interleukin-6 gene promoter with Graves' ophthalmopathy. Autoimmunity 37: 223-226. (Pubitemid 39162679)
9. Chen RH, Chen WC, Wang TY, Tsai CH, Tsai FJ (2005) Lack of association between pro-inflammatory cytokine (IL-6, IL-8 and TNF-alpha) gene polymorphisms and Graves' disease. Int J Immunogenet 32: 343-347. (Pubitemid 41735571)
10. Chen RH, Chang CT, Chen WC, Tsai CH, Tsai FJ (2006) Proinflammatory cytokine gene polymorphisms among Hashimoto's thyroiditis patients. J Clin Lab Anal 20: 260-265.
11. Shiau MY, Huang CN, Yang TP, Hwang YC, Tsai KJ, et al. (2006) Cytokine promoter polymorphisms in Taiwanese patients with Graves' disease. Clin Biochem 40: 213-217.
12. Liu N, Li X, Liu C, Zhao Y, Cui B, et al. (2010) The association of interleukin-1alpha and interleukin-1beta polymorphisms with the risk of Graves' disease in a case-control study and meta-analysis. Hum Immunol 71: 397-401.
13. Slattery ML, Lundgreen A, Bondurant KL, Wolff RK (2011) Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis 32: 1660-1667.
14. Inoue N, Watanabe M, Morita M, Tatusmi K, Hidaka Y, et al. (2011) Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases. Clin Exp Immunol 163: 318-323.
15. Anvari M, Khalilzadeh O, Esteghamati A, Momen-Heravi F, Mahmoudi M, et al. (2010) Graves' disease and gene polymorphism of TNF-alpha, IL-2, IL-6, IL-12, and IFN-gamma. Endocrine 37: 344-348.
16. Larsen P R KHM, Melmed S, Polonsky KS (2003) Williams Textbook of Endocrinology. Elsevier. 1968 p.
17. Ramos E, Lopes C, Barros H (2004) Investigating the effect of nonparticipation using a population-based case-control study on myocardial infarction. Ann Epidemiol 14: 437-441. (Pubitemid 38916573)
18. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, et al. (2007) SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23: 644-645. (Pubitemid 46522604)
19. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57: 289-300.
20. Scheurich P, Thoma B, Ucer U, Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 138: 1786-1790. (Pubitemid 17040802)
21. Kissonerghis AM, Grubeck-Loebenstein B, Pirich K, Feldmann M, Londei M (1989) Tumour necrosis factor synergises with gamma interferon on the induction of mRNA for DR alpha chain on thyrocytes from Graves' disease and non toxic goitre. Autoimmunity 4: 255-266. (Pubitemid 19261057)
22. Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, et al. (2002) The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 41: 329-337. (Pubitemid 34537871)
23. Aust G, Heuer M, Laue S, Lehmann I, Hofmann A, et al. (1996) Expression of tumour necrosis factor-alpha (TNF-alpha) mRNA and protein in pathological thyroid tissue and carcinoma cell lines. Clin Exp Immunol 105: 148-154. (Pubitemid 26231838)
24. Kula D, Jurecka-Tuleja B, Gubala E, Krawczyk A, Szpak S, et al. (2001) Association of polymorphism of LTalpha and TNF genes with Graves' disease. Folia Histochem Cytobiol 39 Suppl 2: 77-78. (Pubitemid 34070768)
25. Bougacha-Elleuch N, Rebai A, Mnif M, Makni H, Bellassouad M, et al. (2004) Analysis of MHC genes in a Tunisian isolate with autoimmune thyroid diseases: implication of TNF -308 gene polymorphism. J Autoimmun 23: 75-80. (Pubitemid 38953795)
26. Kammoun-Krichen M, Bougacha-Elleuch N, Rebai A, Mnif M, Abid M, et al. (2008) TNF gene polymorphisms in Graves' disease: TNF-308 A/G meta-analysis. Ann Hum Biol 35: 656-661.
27. Kutluturk F, Yarman S, Sarvan FO, Kekik C (2013) Association of cytokine gene polymorphisms (IL6, IL10, TNF-alpha, TGF-beta and IFN-gamma) and Graves' disease in Turkish population. Endocr Metab Immune Disord Drug Targets 13: 163-167.
28. Hunt PJ, Marshall SE, Weetman AP, Bunce M, Bell JI, et al. (2001) Histocompatibility leucocyte antigens and closely linked immunomodulatory genes in autoimmune thyroid disease. Clin Endocrinol (Oxf) 55: 491-499. (Pubitemid 32955487)
29. Kroeger KM, Carville KS, Abraham LJ (1997) The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 34: 391-399. (Pubitemid 27368335)
30. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW (1997) Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 94: 3195-3199. (Pubitemid 27157287)
31. Simmonds MJ, Heward JM, Howson JM, Foxall H, Nithiyananthan R, et al. (2004) A systematic approach to the assessment of known TNF-alpha polymorphisms in Graves' disease. Genes Immun 5: 267-273. (Pubitemid 38961159)
32. Gu LQ, Zhu W, Pan CM, Zhao L, Zhang MJ, et al. (2010) Tumor necrosis factor alpha (TNF-alpha) polymorphisms in Chinese patients with Graves' disease. Clin Biochem 43: 223-227.
33. Li N, Zhou ZG, Liu XY, Liu Y, Zhang JJ, et al. (2008) Association of tumour necrosis factor alpha (TNF-alpha) polymorphisms with Graves' disease: A meta-analysis. Clin Biochem 41: 881-886.
34. Cooke GS, Hill AV (2001) Genetics of susceptibility to human infectious disease. Nat Rev Genet 2: 967-977. (Pubitemid 33691093)
35. Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, et al. (2008) Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice. Proc Natl Acad Sci U S A 105: 14034-14039.
36. Chu X, Pan CM, Zhao SX, Liang J, Gao GQ, et al. (2011) A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet 43: 897-901.
37. Chen PL, Fann CS, Chu CC, Chang CC, Chang SW, et al. (2011) Comprehensive genotyping in two homogeneous Graves' disease samples reveals major and novel HLA association alleles. PLoS One 6: e16635.
38. Eriksson N, Tung JY, Kiefer AK, Hinds DA, Francke U, et al. (2012) Novel associations for hypothyroidism include known autoimmune risk loci. PLoS One 7: e34442.
39. Belfer I, Wu T, Hipp H, Walter J, Scully M, et al. (2010) Linkage of large-vessel carotid atherosclerotic stroke to inflammatory genes via a systematic screen. Int J Stroke 5: 145-151.
40. Vangsted AJ, Klausen TW, Gimsing P, Andersen NF, Abildgaard N, et al. (2009) A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica 94: 1274-1281.
41. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, et al. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102: 1369-1376. (Pubitemid 28467565)
42. Weetman AP, Bright-Thomas R, Freeman M (1990) Regulation of interleukin-6 release by human thyrocytes. J Endocrinol 127: 357-361. (Pubitemid 20370584)
43. Ruggeri RM, Barresi G, Sciacchitano S, Trimarchi F, Benvenga S, et al. (2006) Immunoexpression of the CD30 ligand/CD30 and IL-6/IL-6R signals in thyroid autoimmune diseases. Histol Histopathol 21: 249-256. (Pubitemid 43033734)
44. Kallen KJ (2002) The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 1592: 323-343.
45. Barbieri M, Rizzo MR, Papa M, Acampora R, De Angelis L, et al. (2005) Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors. Exp Gerontol 40: 599-604. (Pubitemid 41074806)
46. Berkovic MC, Jokic M, Marout J, Radosevic S, Zjacic-Rotkvic V, et al. (2007) IL-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Exp Mol Pathol 83: 474-479. (Pubitemid 350087037)
47. Papanas N, Papazoglou D, Papatheodorou K, Antonoglou C, Kotsiou S, et al. (2006) Thyroxine replacement dose in patients with Hashimoto disease: a potential role for interleukin-6. Cytokine 35: 166-170. (Pubitemid 44666433)
48. Ruggeri RM, Sciacchitano S, Vitale A, Cardelli P, Galletti M, et al. (2009) Serum hepatocyte growth factor is increased in Hashimoto's thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals. J Endocrinol Invest 32: 465-469.
49. Marinou I, Walters K, Dickson MC, Binks MH, Bax DE, et al. (2009) Evidence of epistasis between interleukin 1 and selenoprotein-S with susceptibility to rheumatoid arthritis. Ann Rheum Dis 68: 1494-1497.
50. Bioque G, Crusius JB, Koutroubakis I, Bouma G, Kostense PJ, et al. (1995) Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol 102: 379-383.
51. Tsai LJ, Hsiao SH, Tsai JJ, Lin CY, Tsai LM, et al. (2009) Higher genetic susceptibility to inflammation in mild disease activity of systemic lupus erythematosus. Rheumatol Int 29: 1001-1011.
52. O'Sullivan BJ, Thomas HE, Pai S, Santamaria P, Iwakura Y, et al. (2006) IL-1 beta breaks tolerance through expansion of CD25+ effector T cells. J Immunol 176: 7278-7287. (Pubitemid 43849028)
53. Chen RH, Chen WC, Chang CT, Tsai CH, Tsai FJ (2005) Interleukin-1-beta gene, but not the interleukin-1 receptor antagonist gene, is associated with Graves' disease. J Clin Lab Anal 19: 133-138. (Pubitemid 41060218)
54. Liu YH, Chen RH, Wu HH, Liao WL, Chen WC, et al. (2010) Association of interleukin-1beta (IL1B) polymorphisms with Graves' ophthalmopathy in Taiwan Chinese patients. Invest Ophthalmol Vis Sci 51: 6238-6246.
55. Khalilzadeh O, Anvari M, Esteghamati A, Mahmoudi M, Tahvildari M, et al. (2009) Graves' ophthalmopathy and gene polymorphisms in interleukin-1alpha, interleukin-1beta, interleukin-1 receptor and interleukin-1 receptor antagonist. Clin Experiment Ophthalmol 37: 614-619.
56. Khalilzadeh O, Anvari M, Esteghamati A, Momen-Heravi F, Mahmoudi M, et al. (2010) The interleukin-1 family gene polymorphisms and Graves' disease. Ann Endocrinol (Paris) 71: 281-285.
57. Jager J, Gremeaux T, Gonzalez T, Bonnafous S, Debard C, et al. (2010) Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes 59: 61-70.
58. Canedo P, Corso G, Pereira F, Lunet N, Suriano G, et al. (2008) The interferon gamma receptor 1 (IFNGR1) -56C/T gene polymorphism is associated with increased risk of early gastric carcinoma. Gut 57: 1504-1508.
59. Fukutani T, Hiromatsu Y, Kaku H, Miyake I, Mukai T, et al. (2004) A polymorphism of interferon-gamma gene associated with changes of antithyrotropin receptor antibodies induced by antithyroid drug treatment for Graves' disease in Japanese patients. Thyroid 14: 93-97. (Pubitemid 38375495)
60. Horie I, Abiru N, Sakamoto H, Iwakura Y, Nagayama Y (2011) Induction of autoimmune thyroiditis by depletion of CD4+CD25 + regulatory T cells in thyroiditis-resistant IL-17, but not interferon-gamma receptor, knockout nonobese diabetic-H2h4 mice. Endocrinology 152: 4448-4454.